Clinical Trials

NCT06026657 | RECRUITING | PHASE1/PHASE2
42 participants

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-23
Start Date:
2024-04-02
Completion:
2027-10-31
Conditions
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT06022757 | TERMINATED | PHASE1/PHASE2
12 participants

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-23
Start Date:
2023-09-20
Completion:
2025-01-13
Conditions
  • Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
  • Urothelial Carcinoma
  • Prostate Cancer
  • Small-cell Lung Cancer
  • Non-small Cell Lung Cancer
  • Cervical Cancer
  • Other Solid Tumors
Interventions
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page